Comparison Between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes Following Cardiac Surgery

Cardiovascular Diseases Clinical Trial

— COPIA  

Official title:

Comparison Between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes Following Cardiac Surgery - a Randomised Controlled Feasibility Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04039854
• Other study ID #: KCH-PRO:19/001
• Secondary ID: 2019-000171-1621
• Status: Recruiting
• Phase: Phase 4
• Start date: November 20, 2019
• Est. completion date: January 31, 2022

Study information

• Verified date: February 2021
• Source: King's College Hospital NHS Trust
• Contact: Kimberley Potter
• Phone: 02079272505
• Email: kimberley.potter[@]LSHTM.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this research proposal is to find out whether comparing the two different anaesthetic maintenance techniques (Propofol vs volatile anaesthetics) in adult patients undergoing heart surgery is practical for the anaesthetist treating the patients and whether it is feasible for the research team to recruit patients and follow them up after the operation.

Description:

All patients undergoing heart bypass surgery are given anaesthetics during the operation. There are two types of anaesthetic commonly given to patients undergoing heart bypass surgery. Propofol is an anaesthetic that is delivered into the patient's vein. Other anaesthetics which are inhaled include Isoflurane, Sevoflurane and Desflurane and these are called volatile anaesthetics. Preliminary studies over the past ten years suggests that maintenance of general anaesthesia using only volatile anaesthetics has the potential to improve health outcomes after bypass surgery, when compared with propofol. Volatile anaesthetics have been shown to protect the heart, the kidneys and the brain, however results of studies have been inconclusive. Currently both volatile anaesthetics and propofol are used equally in clinical practice in the UK.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 31, 2022
• Est. primary completion date: November 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients (male and female) aged 18 years and above
• Written informed consent to participate
• Patients undergoing Coronary Artery Bypass Graft (CABG) surgery on Cardiopulmonary bypass (CPB) with or without valve surgery
• Additive European System for Cardiac Operative Risk Evaluation (EuroSCORE) of 5 or higher

Exclusion Criteria:

• Pregnant or lactating women
• Allergy to propofol
• Previous diagnosis or suspected malignant hyperthermia
• Patients with a known sensitivity to any of the IMPs or other halogenated anaesthetics
• Concomitant therapy with glibenclamide or nicorandil (medications that may interfere with preconditioning)
• Inclusion in another clinical trial of an investigational medicinal product within the last 3 months.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Heart Diseases
• Myocardial Ischemia

Intervention

Drug:
• Isoflurane, Sevoflurane or Desflurane
The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine. The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure. The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU.
• Propofol
Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.

Locations

Country	Name	City	State
United Kingdom	Kings College Hospital NHS Foundation Trust	London
United Kingdom	St Thomas' Hospital	London

Sponsors (3)

Lead Sponsor	Collaborator
King's College Hospital NHS Trust	Guy's and St Thomas' NHS Foundation Trust, London School of Hygiene and Tropical Medicine

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment rate	To identify whether it is feasible to recruit up to 50 patients across 2 tertiary cardiac surgery centres within approximately 10 months.	Collected over the recruitment period of 10 months
Primary	To identify barriers to recruitment.	This data will be completed on a screening log.	Collected over the recruitment period of 10 months
Secondary	Feasibility of maintaining follow-up rates of over 95%	This data will be gathered in the trial database.	Collected over the recruitment period of 10 months
Secondary	Assessment of effectiveness of patient identification and screening processes	To record the number of patients screened and potentially eligible for the trial at the two tertiary cardiac surgery centres within a period of 10 months. This data will be gathered on the screening log.	Collected over the recruitment period of 10 months
Secondary	To investigate whether it is feasible to recruit at least 10% of all potentially eligible patients at the two tertiary cardiac surgery centres within a period of 10 months.	This data will be gathered on screening logs and in the randomisation system.	Collected over the recruitment period of 10 months
Secondary	To investigate whether it is feasible to maintain routine data collection and follow up rates greater than 90% over the trial period.	This data will be gathered in the randomisation site and trial database.	Collected over the full trial period of 24 months
Secondary	To investigate whether it is feasible to achieve 95% data collection of Low Cardiac Output Syndrome for the full trial over the trial period.	This data will be gathered in the trial database.	Collected over the full trial period of 24 months
Secondary	To investigate whether it is feasible to achieve 95% data collection of Myocardial injury, assessed by ischaemic serum markers: hsTnT, MyC, for the full trial over the trial period.	This data will be gathered in the trial database.	Preop, 6 hrs after arrival in CCU, and postop day 1 and 2. Collected over the full trial period of 24 months
Secondary	To investigate whether it is feasible to achieve 90% data collection of MACCE (stroke, non-fatal myocardial infarction, death from any cause) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Cardiac related mortality at 30 days for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Postoperative in hospital atrial fibrillation requiring treatment for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Acute Kidney Injury (according to Kidney Disease: Improving Global Outcomes guidelines) for the full trial over the trial period.	AKI will be confirmed by a 1.5 - 1.9 increase of serum creatinine from baseline or an absolute value rise of creatine greater than 0.3mg/dl (27mmol/L) from baseline. This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of In-hospital postoperative delirium (assessed by the confusion assessment method) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Respiratory complications needing prolonged ventilation (>24 hours) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Length of stay in the critical care unit (CCU) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Length of hospital stay for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of WHO Disability Assessment Schedule (WHODAS) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days post op.
Secondary	To investigate whether it is feasible to achieve 90% data collection of Quality of Life Questionnaire (Euroqol, EQ-5D-5L) for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at Baseline and 30 days postoperative
Secondary	To investigate whether it is feasible to achieve 90% data collection of Days alive and at home for the full trial over the trial period.	This data will be gathered in the trial database.	Data collected at 30 days postoperative